Telomir Pharmaceuticals Inc. has announced promising preclinical results for its investigational compound, Telomir-1 (Zn-Telomir), in animal models of aggressive triple-negative breast cancer (TNBC). The study, conducted in collaboration with BioReperia using zebrafish tumor xenograft models, showed that Telomir-1 significantly reduced primary tumor growth and the spread of cancer cells in models representing biologically distinct forms of TNBC. Notably, Telomir-1 was effective both as a monotherapy and in combination with the chemotherapy agent paclitaxel, particularly in models that were partially or not responsive to chemotherapy. These findings, which have already been completed and reported by the company, will inform future clinical trial designs and patient selection strategies as Telomir Pharmaceuticals continues its IND-enabling activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-000267), on January 05, 2026, and is solely responsible for the information contained therein.